デニファンスタットの市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

Sagimetは、1日1回経口投与する選択的脂肪酸合成酵素（FASN）阻害薬であるデニファンスタット（旧TVB-2640）を、NAFLDの侵攻型であるNASHの治療薬として開発しています。NASH患者では、肝臓におけるFASNを介したパルミチン酸合成の亢進が、肝脂肪の過剰蓄積、炎症、線維化という疾患の3つの重要な促進因子となっています。

2022年11月、Sagimet Biosciencesは、NASH患者を対象としたデニファンスタットによるフェーズIIb臨床試験（FASCINATE-2）の良好な中間データを発表しました。

当レポートでは、主要7市場（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）における非アルコール性脂肪性肝炎（NASH）向けデニファンスタットについて調査分析し、市場規模の予測や、作用機序、用法と用量、研究開発活動などの情報を提供しています。

目次

第1章 レポートのイントロダクション

第2章 非アルコール性脂肪肝炎（NASH）におけるデニファンスタットの概要

• 製品詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期段階の新治療法）

第5章 デニファンスタット市場の評価

• 非アルコール性脂肪肝炎（NASH）におけるデニファンスタットの市場見通し
• 主要7市場の分析
  • 主要7市場の非アルコール性脂肪肝炎（NASH）向けデニファンスタットの市場規模
• 市場の分析：国別
  • 米国の非アルコール性脂肪肝炎（NASH）向けデニファンスタットの市場規模
  • ドイツの非アルコール性脂肪肝炎（NASH）向けデニファンスタットの市場規模
  • 英国の非アルコール性脂肪肝炎（NASH）向けデニファンスタットの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Denifanstat, Clinical Trial Description, 2023
• Table 2: Denifanstat, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Denifanstat Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Denifanstat Market Size in the US, in USD million (2019-2032)
• Table 7: Denifanstat Market Size in Germany, in USD million (2019-2032)
• Table 8: Denifanstat Market Size in France, in USD million (2019-2032)
• Table 9: Denifanstat Market Size in Italy, in USD million (2019-2032)
• Table 10: Denifanstat Market Size in Spain, in USD million (2019-2032)
• Table 11: Denifanstat Market Size in the UK, in USD million (2019-2032)
• Table 12: Denifanstat Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Denifanstat Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Denifanstat Market Size in the United States, USD million (2019-2032)
• Figure 3: Denifanstat Market Size in Germany, USD million (2019-2032)
• Figure 4: Denifanstat Market Size in France, USD million (2019-2032)
• Figure 5: Denifanstat Market Size in Italy, USD million (2019-2032)
• Figure 6: Denifanstat Market Size in Spain, USD million (2019-2032)
• Figure 7: Denifanstat Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Denifanstat Market Size in Japan, USD million (2019-2032)

"Denifanstat Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Denifanstat for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the Denifanstat for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Denifanstat for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Denifanstat market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

Sagimet is developing Denifanstat (formerly TVB-2640) as an oral, once-daily selective fatty acid synthase (FASN) inhibitor to treat NASH, an aggressive form of NAFLD. In patients with NASH, increased FASN-mediated palmitate synthesis in the liver is the source of three key drivers of the disease: excess accumulation of liver fat, inflammation, and fibrosis.

In November 2022, Sagimet Biosciences announced positive interim data from its Phase IIb clinical trial (FASCINATE-2) with denifanstat in NASH patients.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Denifanstat description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on Denifanstat regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Denifanstat research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Denifanstat.
• The report contains forecasted sales of Denifanstat for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for Denifanstat in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Denifanstat Analytical Perspective by DelveInsight

• In-depth Denifanstat Market Assessment

This report provides a detailed market assessment of Denifanstat for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• Denifanstat Clinical Assessment

The report provides the clinical trials information of Denifanstat for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Denifanstat dominance.
• Other emerging products for NASH are expected to give tough market competition to Denifanstat and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Denifanstat in NASH.
• Our in-depth analysis of the forecasted sales data of Denifanstat from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Denifanstat in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of Denifanstat?
• What is the clinical trial status of the study related to Denifanstat in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Denifanstat development?
• What are the key designations that have been granted to Denifanstat for NASH?
• What is the forecasted market scenario of Denifanstat for NASH?
• What are the forecasted sales of Denifanstat in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Denifanstat for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?

Table of Contents

1. Report Introduction

2. Denifanstat Overview in Non-alcoholic Steatohepatitis (NASH)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Denifanstat Market Assessment

• 5.1. Market Outlook of Denifanstat in Non-alcoholic Steatohepatitis (NASH)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Denifanstat in the 7MM for Non-alcoholic Steatohepatitis (NASH)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Denifanstat in the United States for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.2. Market Size of Denifanstat in Germany for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.3. Market Size of Denifanstat in France for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.4. Market Size of Denifanstat in Italy for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.5. Market Size of Denifanstat in Spain for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.6. Market Size of Denifanstat in the United Kingdom for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.7. Market Size of Denifanstat in Japan for Non-alcoholic Steatohepatitis (NASH)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options